Lung cancer. Dacomitinib: getting on target after negative ARCHER trial
- PMID: 25421284
- DOI: 10.1038/nrclinonc.2014.210
Lung cancer. Dacomitinib: getting on target after negative ARCHER trial
Comment on
-
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.Lancet Oncol. 2014 Dec;15(13):1433-1441. doi: 10.1016/S1470-2045(14)70461-9. Epub 2014 Nov 5. Lancet Oncol. 2014. PMID: 25456362 Clinical Trial.
References
-
- Lancet Oncol. 2014 Dec;15(13):1433-41 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
